Evaluation of a Pilot Shard-care Program for Patients With Chronic Pain in the Champlain-LHIN (Shared-Care)
29 april 2022 bijgewerkt door: Ottawa Hospital Research Institute
The study is evaluating an intervention consisting of a five week online mindfulness program for patients being referred to the Pain Clinic and triaged to eConsult.
A pain specialist will be in contact with the patient's family physician to confirm it's appropriate and then a therapist will initiate contact with the patient to assess eligibility.
The therapist will be a registered health professional with experience with patients with chronic health problems and will be supporting the online program where the participant will have communication access to them.
Questionnaires will be sent at three time points to assess changes.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
There are currently many patients waiting to be seen at The Ottawa Hospital Pain Clinic (TOHPC). However, many patients with chronic pain (CP) have exhausted medical options or could be served in the community with appropriate support for them and their family physicians (FPs). eConsult is a secure web-based platform that allows TOHPC physicians to provide pain management advice within seven days within the Champlain Local Health Integration Network (LHIN).
In order to provide enhanced care to patients and improve the uptake of eConsult for CP, the investigators have developed a shared care model for CP in the Champlain LHIN. This program combines the use of eConsult for FPs and a 5-week self-directed online CP management program with therapist support available as needed.
Studietype
Ingrijpend
Inschrijving (Verwacht)
240
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Patricia Poulin, PhD C. Psych
- Telefoonnummer: 73903 6137378899
- E-mail: ppoulin@toh.ca
Studie Locaties
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H8L6
- Ottawa Hospital Research Institute
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- aged 18-years or older
- ability to understand oral and written English
- report chronic pain (≥3months)
Exclusion Criteria:
- refusal or inability to provide informed consent
- severe, unstable or untreated psychiatric conditions (ex. severe depression, psychosis, bipolar, etc.)
- does not have access to the internet or electronic device capable of watching videos
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Online chronic pain management program
There is only one arm.
Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
|
With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program.
The study therapist is a registered health professional.
The program will consist of 5 weeks of mindfulness training.
The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in mean score of the Brief Pain Inventory-Interference Scale (BPI-I)
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The interference scale measures the degree to which pain interferes in the lives of participants in 7 domains: general activity, mood, walking ability, normal work, relations with other persons, sleep and enjoyment of life on a scale from 0 to 10.
The higher the score, the greater the pain interferes with patient's activities.This is a well-validated measure of pain-related disability.
The minimum clinically significant difference is 1 point.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in pain intensity, as measured by the Brief Pain Inventory.
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Brief Pain Inventory (BPI) Pain Severity Scale measures the severity of pain one feels at worst, at least, on average, and at the time of questionnaire completion on a scale from 0 to 10.
The higher the score, the greater the pain severity.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in pain catastrophizing, as measured by the Pain Catastrophizing Scale
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Pain Catastrophizing Scale (PCS) is a 13-item instrument which will evaluate the degree to which patients have negative self-statements and catastrophizing thoughts and ideations when in pain.
The PCS uses a 5-point likert scale (0=not at all, 4=all the time) and consists of three subscales (rumination, magnification, helplessness).
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in mindfulness, as measured by the Short Form Five Facet Mindfulness Questionnaire.
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Mindfulness will be measured using the Short Form Five Facet Mindfulness Questionnaire (FFMQ-SF).
The FFMQ-SF is a 24-item instrument measuring five aspects of mindfulness: Non-reactivity to inner experience, observing, describing, acting with awareness, and non-judging of experience.
Participants are asked to use a 5-point Likert-type scale (1 = never or rarely true; 5 = very often or always true) to rate how true of them they believe each statement to be.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in quality of life, as measured by the EuroQOL-5D
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The EuroQOL-5D (EQ-5D) is a simple-to-use, valid, and sensitive instrument measuring quality of life.
It covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, or severe problems and participants use a tick box to select the statement that is most representative of their conditions.
Participants are also asked to rate, using a visual analogue scale (0 to 100), their state of health.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change from baseline in depressive symptoms, as measured by the Patient Health Questionnaire - 9 scale
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Patient Health Questionnaire - 9 (PHQ-9) is a 9-item scale used to assess the severity of depressive symptoms over the past two weeks and is based on Diagnostic and Statistical Manual (DSM-IV) diagnostic criteria for major depression.
Total scores range from 0 to 27, and clinical cut-points correspond to mild, moderate, moderately severe, and severe depression.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Overall change in status from baseline, as measured by Patient Global Impression of Change scale
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The participants' perceived degree of change in overall status will be measured using the Patient Global Impression of Change (PGIC) scale.
The PGIC uses a 7-point likert scale (very much worse, to very much better) to measure how much the participant feels their overall status has changed since the start of the study.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change from baseline in anxiety symptoms, as measured by the Generalized Anxiety Disorder-7
Tijdsspanne: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Generalized Anxiety Disorder - 7 (GAD-7) is a 7-item scale used to assess the severity of anxiety symptoms over the past two weeks.
Total scores range from 0 to 15, and clinical cut-points correspond to mild, moderate, and severe anxiety.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Patricia Poulin, PhD C. Psych, Ottawa Hospital Research Institute
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Verwacht)
1 september 2022
Primaire voltooiing (Verwacht)
1 maart 2023
Studie voltooiing (Verwacht)
1 maart 2023
Studieregistratiedata
Eerst ingediend
19 maart 2018
Eerst ingediend dat voldeed aan de QC-criteria
8 mei 2018
Eerst geplaatst (Werkelijk)
21 mei 2018
Updates van studierecords
Laatste update geplaatst (Werkelijk)
2 mei 2022
Laatste update ingediend die voldeed aan QC-criteria
29 april 2022
Laatst geverifieerd
1 april 2022
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 20180238-01H
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .